Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Agenus Inc. (AGEN : NSDQ)
 
 • Company Description   
Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.

Number of Employees: 441

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.57 Daily Weekly Monthly
20 Day Moving Average: 4,653,655 shares
Shares Outstanding: 270.99 (millions)
Market Capitalization: $425.46 (millions)
Beta: 1.26
52 Week High: $6.79
52 Week Low: $1.46
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -24.52% -17.35%
12 Week -41.20% -33.91%
Year To Date -51.24% -40.43%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3 FORBES ROAD
-
LEXINGTON,MA 02421
USA
ph: 781-674-4400
fax: 781-674-4200
investor@agenusbio.com None
 
 • General Corporate Information   
Officers
Garo H. Armen - ChiefExecutiveOfficer and Chairman of the Board of
Christine M. Klaskin - Vice President Finance
Brian Corvese - Director
Susan Hirsch - Director
Allison Jeynes-Ellis - Director

Peer Information
Agenus Inc. (CORR.)
Agenus Inc. (RSPI)
Agenus Inc. (CGXP)
Agenus Inc. (BGEN)
Agenus Inc. (GTBP)
Agenus Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00847G705
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 270.99
Most Recent Split Date: 10.00 (0.17:1)
Beta: 1.26
Market Capitalization: $425.46 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.23 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.89 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 15.35
Price/Cash Flow: -
Price / Sales: 1.37
EPS Growth
vs. Year Ago Period: 29.63%
vs. Previous Quarter: 26.92%
Sales Growth
vs. Year Ago Period: 121.36%
vs. Previous Quarter: 28.03%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -8.10
12/31/21 - -10.50
09/30/21 - -1.87
Current Ratio
03/31/22 - 1.78
12/31/21 - 2.12
09/30/21 - 2.05
Quick Ratio
03/31/22 - 1.78
12/31/21 - 2.12
09/30/21 - 2.05
Operating Margin
03/31/22 - -10.04
12/31/21 - -11.81
09/30/21 - -1.64
Net Margin
03/31/22 - -8.04
12/31/21 - -9.72
09/30/21 - 0.38
Pre-Tax Margin
03/31/22 - -8.04
12/31/21 - -9.72
09/30/21 - 0.38
Book Value
03/31/22 - 0.10
12/31/21 - 0.19
09/30/21 - 0.15
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.27
09/30/21 - 0.36
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 21.11
09/30/21 - 26.45
 

Powered by Zacks Investment Research ©